Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Frequently asked questions
What sector does Gain Therapeutics Inc (GANX) operate in?
Gain Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Gain Therapeutics Inc (GANX) current stock price?
As of the latest data, Gain Therapeutics Inc stock price is $1.18, with a previous close of $1.15. Gain Therapeutics Inc gained $0.03 in the last trading session, representing a 2.17% increase.
What is Gain Therapeutics Inc (GANX) current market capitalization?
Gain Therapeutics Inc market cap is approximately 51.28 million.
What is Gain Therapeutics Inc (GANX) Earnings Per Share (EPS)?
The trailing EPS is -$0.50, and the forward EPS is -$0.55.
What is Gain Therapeutics Inc (GANX) EBITDA?
Gain Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -4.54 million.
Does Gain Therapeutics Inc (GANX) pay dividends?
No. Gain Therapeutics Inc does not pay a dividend.
What is Gain Therapeutics Inc (GANX) beta (volatility) score?
Gain Therapeutics Inc has a beta of 0.206, indicating lower volatility than the overall market.
